Advancing cancer diagnostics through AI innovation
Hangzhou DiPath Technology Co., Ltd. is a high-tech medical enterprise dedicated to advancing cancer diagnostics through the power of artificial intelligence and digital pathology.
With over 20 years of combined expertise in AI technology and digital pathology, we have established ourselves as a leader in the field, providing comprehensive solutions from slide scanning to AI-assisted diagnosis.
Our complete product portfolio encompasses the entire pathology workflow, enabling healthcare institutions worldwide to deliver faster, more accurate diagnoses and ultimately improve patient outcomes.
Registration Certificates
Intelligent Analysis Modules
Invention Patents
Cooperative Hospitals
From our founding to becoming a global leader in AI-powered pathology
DiPath was established in Hangzhou, China, with a vision to revolutionize cancer diagnostics through AI and digital pathology technology.
Launched our first AI-powered pathology analysis module, marking the beginning of our comprehensive product portfolio.
Received first NMPA (National Medical Products Administration) approvals for our diagnostic AI modules.
Established partnerships with leading pharmaceutical companies and expanded into international markets.
Achieved CE-IVDR certification for European market entry, meeting the highest international standards.
Surpassed 500 SCI papers, demonstrating our commitment to scientific excellence and research collaboration.
Partnered with nearly 1500 hospitals worldwide and continued to expand our global footprint in digital pathology.
Built from core AI modules into a full workflow platform spanning scanning, analysis, and reporting.
2021
CE-IVDR certification milestone
IP Growth
Continuous expansion of patent portfolio
0
Years
0
Certifications
0
SCI Papers
Visionary leaders driving innovation in digital pathology
Collaborating with industry leaders to advance pathology diagnostics worldwide
Partnering with pharmaceutical leaders to accelerate drug discovery and biomarker development through AI-powered pathology analysis.
Collaborating with microscopy and imaging technology leaders to deliver seamless, integrated pathology solutions.
Working with top research institutions worldwide to advance the science of digital pathology and publish groundbreaking research.
Selected public recognitions and certifications that reflect DiPath's innovation, market adoption, and compliance readiness
Winner in the 2024 AI medical device innovation task jointly announced by MIIT and the NMPA.
Ranked No. 37 in the 2024 Top 100 for Innovative Devices & Intelligent Manufacturing.
Named in public reports among Zhejiang's selected "Technology Little Dragon" enterprises.
20+ medical device registrations from National Medical Products Administration
European In Vitro Diagnostic Device certification for EU market
Information Security Management System certification
Placeholder items prepared for upcoming official announcements.
News Placeholder
Official event details will be updated after business confirmation.
Event Placeholder
Session schedule and speaker lineup will be published in the next update.
Exhibition Placeholder
Regional dates and venue links are reserved pending release.
Join our team of innovators, researchers, and healthcare professionals dedicated to transforming cancer diagnostics through AI.
